Phase II study of BI1482694 in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

被引：0
|
作者：
Janne, P. A. [1 ]
Son, J. [2 ]
Voccia, I. [3 ]
Uttenreuther-Fischer, M. [4 ]
Park, K. [5 ]
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Hanmi Pharmaceut Co Ltd, R&D, Seoul, South Korea
[3] Boehringer Ingelheim Canada Ltd, Clin Operat, Burlington, ON, Canada
[4] Boehringer Ingelheim Pharma GmbH & Co KG, TA Oncol, Biberach, Germany
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
476TiP
引用
收藏
页码：145 / 145
页数：1
相关论文
共 50 条
  • [1] Phase II study of BI1482694 in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
    Sun, J.
    Wang, Y. -M.
    Duan, Y. -Z.
    ANNALS OF ONCOLOGY, 2015, 26 : 145 - 145
  • [2] ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
    Ou, Sal -Hong
    Park, Keunchil
    Han, Ji-Youn
    Kim, Dong-Wan
    Bazhenova, Lyudmila
    Pang, Yong-Kek
    Hin, How Soon
    Juan, Oscar
    Son, Jeewoong
    Voccia, Isabelle
    Massey, Daniel
    Kim, Miyoung
    Janne, Pasi A.
    CANCER RESEARCH, 2016, 76
  • [3] ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
    Park, K.
    Han, J. -Y.
    Kim, D. -W.
    Bazhenova, L. A.
    Ou, S. -H.
    Pang, Y. -K.
    Hin, H. S.
    Juan, O.
    Song, J.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S139 - S139
  • [4] Clinical activity and safety of the EGFR mutant-specific inhibitor, BI1482694, in patients (pts) with T790M-positive NSCLC
    Lee, J. -S.
    Park, K.
    Han, J. -Y.
    Lee, K. H.
    Kim, J. -H.
    Cho, E. K.
    Cho, J. Y.
    Min, Y. J.
    Kim, J. -S.
    Kim, H. -G.
    Kim, B. -S.
    Jung, J.
    Kim, D. -W.
    ANNALS OF ONCOLOGY, 2015, 26 : 128 - 129
  • [5] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Joan Rou-En Choo
    Chee-Seng Tan
    Ross A. Soo
    Targeted Oncology, 2018, 13 : 141 - 156
  • [6] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Choo, Joan Rou-En
    Tan, Chee-Seng
    Soo, Ross A.
    TARGETED ONCOLOGY, 2018, 13 (02) : 141 - 156
  • [7] Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer
    Matsumoto, Yoshiya
    Kawaguchi, Tomoya
    Yamamoto, Norio
    Sawa, Kenji
    Yoshimoto, Naoki
    Suzumura, Tomohiro
    Watanabe, Tetsuya
    Mitsuoka, Shigeki
    Asai, Kazuhisa
    Kimura, Tatsuo
    Yoshimura, Naruo
    Kuwae, Yuko
    Hirata, Kazuto
    INTERNAL MEDICINE, 2017, 56 (17) : 2325 - 2328
  • [8] Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Disease control with a second epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) after failure of a first TKI in Asian patients with non-small cell lung cancer (NSCLC)
    Wong, A.
    Lim, S. W.
    Chin, T. M.
    Soong, R.
    Soo, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M-positive non-small cell lung cancer (NSCLC) European subset
    Tiseo, M.
    Santo, A.
    Hochmair, M. J.
    Geldart, T.
    Metro, G.
    Hanrahan, E.
    Lamberg, K.
    Moran, T.
    Nyhus, C.
    Paredes, A.
    Vansteenkiste, J. F.
    Vicente, D.
    Miranda, M.
    Rigas, J.
    de Marinis, F.
    ANNALS OF ONCOLOGY, 2018, 29
12345